INVA — Innoviva, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1080014 ·
Last close
$20.87
Market Cap
$1.51B
52W High
$25.15
52W Low
$16.52
ADV30
927,623
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 119,591,000 | 90,616,000 | 50,855,000 | -83,420,000 | 1,702,727,000 | 570,388,000 | 469,465,000 |
| Mar 2026 | 97,994,000 | 82,387,000 | 38,154,000 | 186,595,000 | 1,836,587,000 | 603,085,000 | 494,932,000 |
| Dec 2025 | 114,613,000 | 101,944,000 | 38,988,000 | 164,153,000 | 1,635,165,000 | 550,941,000 | 462,324,000 |
| Sep 2025 | 107,800,000 | 75,539,000 | 34,578,000 | 89,908,000 | 1,429,106,000 | 476,513,000 | 419,155,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$183,595,000
Investing CF
$112,178,000
Financing CF
$-11,778,000
CapEx
$-4,502,000
Dividends Paid
—
Buybacks
$-25,013,000
EPS Diluted TTM
$6.01
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$455,963,000
Inventory
$38,843,000
Receivables
$92,628,000
ST Investments
$8,846,000
EBIT TTM
$617,438,000
Pretax Income TTM
$600,014,000
Interest Exp TTM
$17,424,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$439,998,016
EBITDA
$195,387,008
Free Cash Flow
$110,332,496
Enterprise Value
$1,244,774,784
Total Cash
$579,056,000
Total Debt
$331,239,008
Shares Out
72,245,485
Trailing EPS
$4.31
Book Value
$16.98
ROE
36.7%
ROA
6.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 411,328,000 | 163,745,000 | 271,165,000 | 1,635,165,000 | 462,324,000 | 1,172,841,000 | 196,930,000 |
| Dec 2024 | 358,711,000 | 166,867,000 | 23,392,000 | 1,301,060,000 | 609,901,000 | 691,159,000 | 188,690,000 |
| Dec 2023 | 310,463,000 | 113,885,000 | 179,722,000 | 1,243,507,000 | 568,552,000 | 674,955,000 | 141,064,000 |
| Dec 2022 | 331,339,000 | 206,995,000 | 213,921,000 | 1,231,497,000 | 665,709,000 | 565,788,000 | 201,726,000 |
TTM Snapshot
Revenues TTM
$420,690,000
NetIncome TTM
$504,344,000
OpCashFlow TTM
—
Assets (Latest)
$1,836,587,000
Forward EPS
$2.21
Max Pain — expiry 2026-12-18
max pain strike: $22.50 · spot: $21.06 · call oi: 924 · put oi: 245
Expected Move to 2026-12-18:
±$2.30
(10.92%) —
implied range
$18.76 –
$23.36
· ATM straddle on $20.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical Inc. | $1.51B | $15.29 | — |
| SNDX | Syndax Pharmaceuticals Inc | $1.51B | $16.90 | — |
| KRSA | Korsana Biosciences, Inc. | $1.53B | $33.51 | — |
| STOK | Stoke Therapeutics, Inc. | $1.55B | $23.95 | — |
| QURE | uniQure N.V. | $1.56B | $22.54 | — |
News headlines (Yahoo Finance, 1h cache)
Is Innoviva (INVA) Undervalued As Zacks Flags Its Value Appeal?
2026-10-08 19:19 · Yahoo
INVA vs. MRK: Which Stock Is the Better Value Option?
2026-10-08 14:40 · Yahoo
Should Value Investors Buy Innoviva (INVA) Stock?
2026-10-08 12:40 · Yahoo
Innoviva to Participate in Upcoming Investor Conferences
2026-09-02 12:00 · Yahoo
Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
2026-08-11 20:05 · Yahoo
Innoviva (INVA) Q2 Earnings and Revenues Top Estimates
2026-08-06 00:35 · Yahoo
Is Innoviva (INVA) One of the Best Cheap Small Cap Stocks to Buy Now?
2026-07-01 19:36 · Yahoo
5 Attractive Low Price-to-Sales Stocks With Promising Upside Potential
2026-10-08 12:54 · Yahoo
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
2026-08-05 20:05 · Yahoo
AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates
2026-07-31 12:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.